New evidence–based clinical practice guidelines from the Alzheimer’s Association provide updated recommendations on evaluating individuals suspected of having Alzheimer’s disease (AD) and AD ...
The Alzheimer’s disease market is expected to grow at a high compound annual growth rate (CAGR) of 23.4% from $2.4bn in 2023 to $19.3bn by 2033 across the eight major markets (8MM) (US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback